In a strategic move to fortify its cardiovascular and metabolic disease pipeline following a sequence of high-profile clinical and commercial…
Read More
Sample ages bolster a rising tide doubting a singular 3.9 billion-year-old lunar cataclysm
The long-held theory of a singular, cataclysmic bombardment of the inner solar system, often referred to as the Late Heavy…
Read More
Seven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
The U.S. Food and Drug Administration (FDA) has announced the initial cohort of seven pharmaceutical companies selected to participate in…
Read More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Bolster Immunology Pipeline
AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
Biogen Acquires RayThera for Up to $1 Billion to Bolster Immunology Pipeline
Biogen Inc. has announced a definitive agreement to acquire RayThera, a privately held biotechnology company focused on developing small-molecule therapies…
Read More
SK bioscience and VECOL Forge Strategic Partnership to Bolster Vaccine Self-Sufficiency in Colombia
SK bioscience has signed a significant vaccine technology transfer and manufacturing agreement with Colombia’s state-owned pharmaceutical company, VECOL. This collaboration…
Read More
UK Secures Favipiravir Supply from Japan to Bolster Hantavirus Preparedness
The United Kingdom has received a crucial supply of the antiviral medication favipiravir from the Japanese government, a strategic move…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read More
Bayer Acquires Perfuse Therapeutics for Up to $2.45 Billion to Bolster Ophthalmology Pipeline with Novel Endothelin Receptor Antagonist
Bayer AG is set to significantly expand its presence in the ophthalmology market with the acquisition of Perfuse Therapeutics, a…
Read More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion to Bolster Autoimmune Disease Pipeline with Novel T-Cell Engagers
UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read MoreYOU MAY HAVE MISSED
